Luxa Biotechnology
Business Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2050 Center Ave Ste 435, Fort Lee, New J...Phone Number
(201) 482-4093Website
www.luxabiotech.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Luxa Biotechnology
Luxa Biotechnology, LLC is dedicated to improving the lives of patients through innovative drug development programs. The company focuses on treating dry age-related macular degeneration (AMD) by implanting adult stem cell-derived retinal pigment epithelial cells to prevent or reverse vision loss. With an open innovation strategy, Luxa leads in the biotechnology sector, emphasizing cutting-edge technology and research. Their mission is to ensure long-term well-being and quality of life for patients.Explore more
Luxa Biotechnology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Luxa Biotechnology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Luxa Biotechnology had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Luxa Biotechnology has recently received funding, and reach out quickly before it becomes old news!
Luxa Biotechnology, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Luxa Biotechnology has new funding data
Product Launch: Get notified when Luxa Biotechnology launches new products
Earning: See what the market has to say on Luxa Biotechnology recently announced quarterly report
Check out if Luxa Biotechnology is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Luxa Biotechnology
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Luxa Biotechnology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Luxa Biotechnology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Luxa Biotechnology.
Luxa Biotechnology Tech Stack
A closer look at the technologies used by Luxa Biotechnology
Luxa Biotechnology News & Media
Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills Eye Conference
FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced clinical data from its Phase 1/2a clinical trial evaluating RPESC-RPE-4W, a proprietary retinal pigment epithelium (RPE) cell therapy for patients with dry age-related macular degeneration (dry AMD). The data were presented today at the 77th Annual WillsLuxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration
FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RPESC-RPE-4W transplantation for the treatment of patients with dry age-related macular degeneration (dry AMD). RPESC-RPE-4W is a ceLuxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), today announced the appointment of Keith Dionne, Ph.D. as Chief Executive Officer. An early pioneer in the cell therapy field and a seasoned biotechnology executive, Dr. Dionne brings three decades of experience to Luxa and will be instrumental in advancing RPESC thera
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Luxa Biotechnology
Sign Up For FreeTo access detailed company insights
Luxa Biotechnology, LLC is dedicated to improving the lives of patients through innovative drug development programs. The company focuses on treating dry age-related macular degeneration (AMD) by implanting adult stem cell-derived retinal pigment epithelial cells to prevent or reverse vision loss. With an open innovation strategy, Luxa leads in the... Read More
